Procalcitonin in Hepatocellular Carcinoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Iman Fawzy Montasser, Ain Shams University
ClinicalTrials.gov Identifier:
NCT01518829
First received: January 24, 2012
Last updated: September 29, 2013
Last verified: September 2013
  Purpose

the value of serum procalcitonin in differentiation between bacterial infection and non infectious inflammation in febrile HCC patients following locoeregional treatment for HCC.


Condition
Hepatocellular Carcinoma

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Role of Procalcitonin in Differantiation Between Bacerial Infection and Non Infectious Inflammation in Febrile Hepatocellular Carcinoma Patients After Locoregional Treatment

Resource links provided by NLM:


Further study details as provided by Ain Shams University:

Primary Outcome Measures:
  • Differantiate between post- embolization syndrom and sepsis following locoregional treatment for hepatocellular carcinoma [ Time Frame: 6months ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   Samples Without DNA

Serum


Enrollment: 42
Study Start Date: April 2012
Study Completion Date: January 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Patients with hepatocellular carcinoma
Patients with hepatocellular carcinoma who will undergo locoregional therapy
patients with chronic liver disease
patients with chronic liver disease, as a control group

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

inpatients in tropical medicine department and hepatocellular carcinoma out patient clinic ain shams university

Criteria

Inclusion Criteria:

  1. - Hepatocellular carcinoma patients who will undergo TACE and/or radio-frequency.
  2. - Fever more than 38C after 48 hours post intervention.

Exclusion Criteria:

  1. HCC Patients who does not develop fever after intervention.
  2. Proven infection elsewhere (e.g. UTI, chest infection..)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01518829

Locations
Egypt
Tropical medicine department and hepatocellular carcinoma clinic
Cairo, Egypt
Sponsors and Collaborators
Ain Shams University
Investigators
Principal Investigator: Hisham K Dabbous, professor Tropical medicine department
  More Information

No publications provided

Responsible Party: Iman Fawzy Montasser, Lecturer of Tropical medicine ,Faculty of Medicine,Ain Shams university, Ain Shams University
ClinicalTrials.gov Identifier: NCT01518829     History of Changes
Other Study ID Numbers: HCC and Procalcitonin
Study First Received: January 24, 2012
Last Updated: September 29, 2013
Health Authority: Egypt: Institutional Review Board

Keywords provided by Ain Shams University:
hepatocellular carcinom
postablation syndrom
procalcitonin

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Carcinoma
Adenocarcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases

ClinicalTrials.gov processed this record on October 01, 2014